Nevirapine Levels after Discontinuation of Rifampicin Therapy and 60‐Week Efficacy of Nevirapine‐Based Antiretroviral Therapy in HIV‐Infected Patients with Tuberculosis
Open Access
- 1 January 2007
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (1) , 141-144
- https://doi.org/10.1086/510078
Abstract
Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study. After discontinuation of rifampicin therapy, mean nevirapine levels (±; standard deviation) increased from 5.4 ±; 3.5 mg/L to 6.4 ±; 3.4 mg/L (P = .047), but no nevirapine-related adverse events occurred. There was no statistically significant difference in 60-week antiviral efficacy between these patients and patients receiving nevirapine-based antiretroviral therapy alone (P > .05).Keywords
This publication has 9 references indexed in Scilit:
- Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and Without Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Plasma Nevirapine Levels and 24‐Week Efficacy in HIV‐Infected Patients Receiving Nevirapine‐Based Highly Active Antiretroviral Therapy with or without RifampicinClinical Infectious Diseases, 2006
- Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugsAIDS, 2005
- Pharmacokinetic Drug Interactions with NevirapineJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Liver toxicity caused by nevirapineAIDS, 2002
- Pharmacokinetic Interaction Between Nevirapine and Rifampicin in HIV-Infected Patients With TuberculosisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Sex Differences in Nevirapine RashClinical Infectious Diseases, 2001
- Effect of tuberculosis therapy on nevirapine trough plasma concentrationsAIDS, 1999
- Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patientsEuropean Respiratory Journal, 1998